55. Relapsing polychondritis Clinical trials / Disease details
Clinical trials : 8 / Drugs : 10 - (DrugBank : 9) / Drug target genes : 12 - Drug target pathways : 101
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05168475 (ClinicalTrials.gov) | July 14, 2021 | 9/12/2021 | Biologics in Refractory Vasculitis | Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and Children | Giant Cell Arteritis;Takayasu Arteritis;Cogan Syndrome;Relapsing Polychondritis;Cryoglobulinemic Vasculitis;IgA Vasculitis;Polyarteritis Nodosa;Cutaneous Polyarteritis Nodosa;Primary Angiitis of Central Nervous System | Biological: Rituximab;Biological: Infliximab;Biological: Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | NULL | Recruiting | 5 Years | N/A | All | 140 | Phase 2 | United Kingdom |
| 2 | EUCTR2019-003964-30-GB (EUCTR) | 22/10/2020 | 31/07/2020 | Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children. | Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS) | Non-ANCA associated vasculitides: 1.Giant cell arteritis (GCA)2.Takayasu’s arteritis (TA)3.Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN)4.Relapsing polychondritis (RP)5.IgA vasculitis (IgAV)6.Cogan’s syndrome7.Non-infective cryoglobulinaemia8.Primary angiitis of central nervous system (PACNS) MedDRA version: 21.1;Level: PT;Classification code 10047115;Term: Vasculitis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Infliximab Product Code: N/A INN or Proposed INN: Infliximab Trade Name: Rituximab Product Name: Rituximab INN or Proposed INN: Rituximab Trade Name: Tocilizumab Product Name: Tocilizumab Product Code: N/A INN or Proposed INN: Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 2 | United Kingdom | ||
| 3 | NCT04077736 (ClinicalTrials.gov) | September 10, 2019 | 1/9/2019 | Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis | A Pilot Study of Low Dose IL-2 in the Treatment of Relapsing Polychondritis | Relapsing Polychondritis | Drug: Interleukin-2 | Peking University People's Hospital | NULL | Not yet recruiting | 18 Years | 70 Years | All | 10 | Phase 2 | NULL |
| 4 | JPRN-UMIN000006950 | 2011/12/01 | 26/12/2011 | Effects of additional inhaled tiotropium in relapsing polychondritis with airway involvement | Effects of additional inhaled tiotropium in relapsing polychondritis with airway involvement - Inhaled Tiotropium in RP | Relapsing polychondritis | To record subjective symptoms, pulmonary function, airway diameter and dimension 3 months before, at baseline and 3 months following tiotropium | St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 20 | Not selected | Japan |
| 5 | NCT01272856 (ClinicalTrials.gov) | January 2011 | 6/1/2011 | Study on the Safety of Abatacept in Relapsing Polychondritis | An Open-Label, Single-Center, Phase I Study on the Safety of Abatacept in Relapsing Polychondritis | Relapsing Polychondritis | Drug: Abatacept | Benaroya Research Institute | Bristol-Myers Squibb | Completed | 18 Years | 80 Years | Both | 4 | Phase 1 | United States |
| 6 | JPRN-UMIN000003869 | 2010/07/01 | 05/07/2010 | A clinical study to establish in diagnostic criteria and treatment guideline of relapsing polychondritis. | A clinical study to establish in diagnostic criteria and treatment guideline of relapsing polychondritis. - Diagnostic and treatment guideline of relapsing polychondritis | Relapsing polychondritis | corticosteroid+methotrexate corticosteroid+ciclosporin | St. Marianna University School of Medicine | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan |
| 7 | NCT01104480 (ClinicalTrials.gov) | May 2010 | 13/4/2010 | Tocilizumab for Relapsing Polychondritis | Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis | Relapsing Polychondritis | Drug: Tocilizumab | McMaster Children's Hospital | NULL | Withdrawn | 12 Years | 15 Years | Male | 0 | Phase 2 | Canada |
| 8 | NCT01041248 (ClinicalTrials.gov) | January 2010 | 30/12/2009 | Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab | Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis | Relapsing Polychondritis | Drug: Tocilizumab | Children's Hospital of Eastern Ontario | NULL | Completed | N/A | N/A | Male | 1 | N/A | Canada |